Immunocore Holdings plc (IMCR) is a Biotechnology company in the Healthcare sector, currently trading at $31.69. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is IMCR = $47 (+49.1% upside).
Valuation: IMCR trades at a trailing Price-to-Earnings (P/E) of -59.7 (S&P 500 average ~25).
Financials: revenue is $298M, +31.3%/yr average growth. Net income is $26M (loss), growing at +7.3%/yr. Net profit margin is -8.9% (negative). Gross margin is 97.9% (-1.8 pp trend).
Balance sheet: total debt is $44M against $381M equity (Debt-to-Equity (D/E) ratio 0.11, conservative). Current ratio is 4.04 (strong liquidity). Debt-to-assets is 4.1%. Total assets: $1.1B.
Analyst outlook: 9 / 14 analysts rate IMCR as buy (64%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 83/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 66/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).
